国药一致:2024年报净利润6.42亿 同比下降59.85%

Financial Performance - The company's basic earnings per share decreased to 1.15 yuan, a decline of 59.93% compared to 2.87 yuan in the previous year [1] - Net profit fell to 6.42 billion yuan, down 59.85% from 15.99 billion yuan in the previous year [1] - Operating revenue slightly decreased to 74.378 billion yuan, a reduction of 1.46% from 75.477 billion yuan in the previous year [1] - Return on equity dropped to 3.67%, down 61.61% from 9.56% in the previous year [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 35,592.8 million shares, accounting for 64.79% of the circulating shares, with a decrease of 599.67 million shares compared to the previous period [2] - The largest shareholder, China National Pharmaceutical Group Corporation, holds 30,484.25 million shares, maintaining its position [3] - New entrants among the top shareholders include several investment funds, indicating a shift in the shareholder composition [3] Dividend Distribution - The company announced a dividend distribution of 3.66 yuan per share (including tax) [4]